From the Journals

Th17-associated cytokines, CRP fail as biomarkers for ustekinumab success in PsA


 

FROM ARTHRITIS & RHEUMATOLOGY

Neither baseline Th17-associated cytokines nor C-reactive protein levels were predictive of response to ustekinumab in patients with psoriatic arthritis, despite significant reductions following treatment, according to Stefan Siebert, PhD, of the University of Glasgow (Scotland) and associates.

In a study published in Arthritis & Rheumatology, the authors retrospectively analyzed serum samples collected from 927 patients with psoriatic arthritis who participated in the phase 3 PSUMMIT trials. Patients received ustekinumab (Stelara) or placebo, and samples were collected at baseline, 4 weeks, and 24 weeks.

At baseline, interleukin-17A, -17F, and -23 levels were associated with skin disease scores, but neither these nor C-reactive protein (CRP) were associated with joint disease scores. While IL-17A, IL-17F, and CRP were reduced in patients who responded to ustekinumab, baseline levels of IL-17A, IL-17F, IL-23, and CRP were not associated with ustekinumab response in either skin or joints.

In patients who achieved a 75% reduction in their Psoriasis Area and Severity Index scores or a 20% reduction in their American College of Rheumatology response score after 24 weeks, CRP levels were significantly lower than in patients who did not achieve these scores (51%-58% vs. 32%-33%; P less than .05). However, IL-17A and IL-17F levels were not significantly different in these patients.

“While the biomarkers studied in the PSUMMIT program did not translate into therapeutic utility, it is important that relevant biomarker studies associated with phase 3 clinical trial programs are published in order to increase our understanding of this complex disease and further dissect the role of the IL-23/IL-17 pathway,” the investigators concluded.

The study was funded by Janssen; four coauthors reported being employed with Janssen.

SOURCE: Siebert S et al. Arthritis Rheumatol. 2019 May 9. doi: 10.1002/art.40921.

Recommended Reading

Proinflammatory diet may not trigger adult psoriasis, PsA, or AD
MDedge Dermatology
AFib, CVD risks similar after ustekinumab and TNF inhibitors in psoriatic patients
MDedge Dermatology
TNF-alpha, adiponectin potential biomarkers for PsA, psoriasis differentiation
MDedge Dermatology
FDA approves IL-23 inhibitor risankizumab for treating plaque psoriasis
MDedge Dermatology
FDA approves new etanercept biosimilar, Eticovo
MDedge Dermatology
Positive psoriatic arthritis screens occur often in psoriasis patients
MDedge Dermatology
Surprise! MTX proves effective in psoriatic arthritis
MDedge Dermatology
PsA patients had durable responses after 1 year of IV golimumab treatment
MDedge Dermatology
Weight loss improves psoriatic arthritis
MDedge Dermatology
Etanercept biosimilar SB4 a cost-effective alternative for psoriasis, PsA
MDedge Dermatology